[PDF][PDF] T 细胞受体基因工程T 细胞治疗的现状与未来
王丹阳， 熊昕昕， 刘海平， 周鹏辉 - PROGRESS IN …, 2021 - pps.cpu.edu.cn
… Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J].
J Immunother, 2013, 36(2): 133-151. [27] Kuhns MS, Davis MM, Garcia K C. …
J Immunother, 2013, 36(2): 133-151. [27] Kuhns MS, Davis MM, Garcia K C. …
T 细胞受体基因工程T 细胞治疗的现状与未来
王丹阳， 熊昕昕， 刘海平， 周鹏辉 - 药学进展, 2021 - pps.cpu.edu.cn
… Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J].
J Immunother, 2013, 36(2): 133-151. [27] Kuhns MS, Davis MM, Garcia K C. …
J Immunother, 2013, 36(2): 133-151. [27] Kuhns MS, Davis MM, Garcia K C. …
实体肿瘤TCR-T 治疗研究的现状与面临的挑战.
叶春梅， 叶韵斌 - Chinese Journal of Cancer Biotherapy, 2020 - search.ebscohost.com
… Therefore,this paper summarizes the research status of TCR-T therapy for solid tumors in …
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J]. J …
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J]. J …
T 细胞受体工程化T 细胞疗法的临床研究及动物肿瘤模型的应用
王琨， 汪金姣， 王皞鹏 - 药学进展, 2021 - pps.cpu.edu.cn
… Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy[J].
J Immunother, 2013, 36(2): 133-151. [65] Rongvaux A, Willinger T, Martinek J, et al. …
J Immunother, 2013, 36(2): 133-151. [65] Rongvaux A, Willinger T, Martinek J, et al. …
TCR-T 免疫治疗肿瘤: 现状, 挑战及展望
郑伟涛， 李涵泺， 胡康洪 - 中国癌症杂志, 2023 - china-oncology.com
… the differences between TCR-T therapy and CAR-T therapy in recognizing cancer antigens,
… Cancer regression and neurological toxicity following antiMAGE-A3 TCR gene therapy[J]. J …
… Cancer regression and neurological toxicity following antiMAGE-A3 TCR gene therapy[J]. J …
[HTML][HTML] KRAS G12V 特异性T 细胞受体治疗恶性肿瘤的临床前研究
程晓静， 蒋栋， 张连海， 王江华， 李雅真… - Journal of Peking …, 2022 - ncbi.nlm.nih.gov
… brain were observed. We also found that KVA11-01 TCR-T could significantly infiltrate into
tumor … -01 TCR; D, flow fluorescence signal was detected after transfer of lentivirus candidate …
tumor … -01 TCR; D, flow fluorescence signal was detected after transfer of lentivirus candidate …
TCR-T 细胞免疫疗法治疗肝细胞癌的研究现状及策略
胡伟， 何美芳 - 中华普通外科学文献(电子版), 2021 - zhptwkxwx.cma-cmc.com.cn
… Some strategies are proposed, including optimizing TCR affinity, reducing toxicity,
reducing mismatch of double strand in exogenous and endogenous TCR, improving tumor …
reducing mismatch of double strand in exogenous and endogenous TCR, improving tumor …
[HTML][HTML] 以T 细胞受体为基础的免疫疗法研究进展
陈缘， 高福， 谭曙光 - 生物工程学报, 2023 - cjb.ijournals.cn
… of clinical tumor treatment and become critical strategies for treating multiple tumors. T cell
receptor (TCR) … Complete regression of metastatic cervical cancer after treatment with human …
receptor (TCR) … Complete regression of metastatic cervical cancer after treatment with human …
[PDF][PDF] T 细胞受体工程化T 细胞的临床应用及肿瘤特异性抗原和T 细胞受体的筛选策略
黄倩茹， 朱一成， 李扬扬， 李斌 - … IN PHARMACEUTICAL SCIENCES, 2021 - pps.cpu.edu.cn
… TCR prediction is summarized, and different screening strategies for tumor-specific antigens
and corresponding TCRs … to provoke new insight for further development of TCR-T therapy. …
and corresponding TCRs … to provoke new insight for further development of TCR-T therapy. …
靶向肿瘤驱动抗原的T 细胞受体工程化T 细胞治疗策略
罗凌杰， 汤宇翔， 梁文华， 谭润琳， 钱威瑾， 王锋 - 药学进展, 2021 - pps.cpu.edu.cn
… tumor driver antigens. This paper summarizes the recent progress of tumor driver mutation
antigens and the strategy of TCR… and mouse T-cell receptors mediates cancer regression and …
antigens and the strategy of TCR… and mouse T-cell receptors mediates cancer regression and …